Monthly Prescribing Reference

Gvoke Kit Now Available for Severe Hypoglycemia

The new Gvoke Kit formulation is available as a 1mg/0.2mL single-dose vial and syringe kit. Gvoke ® Kit is now available for the treatment of severe hypoglycemia in adult and pediatric patients with ...
Business Wire

Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of ...

The use of glucose tablets to treat hypoglycemia during and after exercise was less with RTU glucagon when compared to standard of care. Treatment-emergent adverse events with a mini dose of RTU ...
Business Wire

Xeris Pharmaceuticals Announces Positive Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Ready-to-Use (RTU) Micro™ Glucagon in Adults at Risk ...

Leveraging XeriSol™, one of Xeris’ two proprietary formulation technology platforms, Xeris has the potential to provide the first ready-to-use, room-temperature stable liquid glucagon for use by ...